Pyridine-based thyroid receptor ligands

• US 6,747,048 B2
• Filed: 05/07/2003
• Issued: 06/08/2004
• Est. Priority Date: 05/08/2002
• Status: Expired due to Fees

• Current Assignee: Bristol-Myers Squibb Company
• Original Assignee: Bristol-Myers Squibb Company
• Inventors: Zhang, Minsheng, Caringal, Yolanda, Hangeland, Jon, Friends, Todd
• Primary Examiner(s): NORTHINGTON DAVIS, ZINNA
• Application Number:
  US10/431,269
• Publication Number:
  US 20040039028A1
• Time in Patent Office: 398 Days
• Field of Search: 546/296, 546/297, 546/307, 546/312, 546/339, 546/343, 546/344, 514/345, 514/348, 514/349, 514/352
• US Class Current: 514/349
• CPC Class Codes: C07D 213/68 attached in position 4
• CPC Class Codes: C07D 213/69 Two or more oxygen atoms
• CPC Class Codes: C07D 213/70 Sulfur atoms
• CPC Class Codes: C07D 213/73 Unsubstituted amino or imino radicals
• CPC Class Codes: C07D 213/74 Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• CPC Class Codes: C07D 213/75 Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
• CPC Class Codes: C07D 401/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 405/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 409/12 linked by a chain containing hetero atoms as chain links

Abstract

Novel pyridine-based thyroid receptor ligands are provided which have the general formula I

wherein:

X is oxygen (—O—), sulfur (—S—), sulfoxide (—S(O)—), sulfonyl (—SO₂—), CR₈R₈ or NR₈;

Y is —NR₈, oxygen (—O—), —CH₂— or sulfur (—S—);

Z is a bond or substituted or unsubstituted C_1-4 alkyl; and

wherein the substituents are as described herein.

In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T₃ regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

Claims

1. A compound of the formula

wherein

X is selected from the group consisting of oxygen, sulfur, sulfoxide, sulfonyl, —

CR₈R₈′ and

—

NR₈;

Y is selected from the group consisting of —

NR₈, oxygen, —

CH₂— and

sulfur;

Z is a bond or substituted or unsubstituted C_1-4 alkyl;

R₁ is selected from the group consisting of halogen, trifluoromethyl, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryloxy, substituted amide, sulfone, sulfonamide and C_3-7 cycloalkyl, wherein said aryl, heteroaryl or cycloalkyl ring(s) are attached or fused to the aromatic ring;

R_1a is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

R₂ and R₃ are each independently selected from the group consisting of hydrogen, halogen, unsubstituted or substituted C_1-4 alkyl and unsubstituted or substituted C_3-5 cycloalkyl, wherein at least one of R₂ and R₃ being other than hydrogen;

R₄ is selected from the group consisting of hydrogen, halogen, amino, O—

R₇ and S—

R₇;

R₅ is selected from the group consisting of hydroxyl, carboxylic acid, sulfonic acid and phosphonic acid;

R₆ is selected from the group consisting of hydrogen, alkyl, alkanoyl and aroyl;

R₇ is hydrogen or C_1-4 alkyl;

R₈ for each occurrence is independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, arylalkyl or substituted arylalkyl, alkoxy and hydroxyl; and

R₈′

is selected from the group consisting of hydrogen, a bond, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, arylalkyl or substituted arylalkyl, alkoxy and hydroxyl, or R₈ and R₈′

together form a carbonyl,

including all prodrug, stereoisomers and pharmaceutically acceptable salts thereof.

2. The compound as defined in claim 1 wherein

X is selected from the group consisting of oxygen, sulfur, sulfoxide, sulfonyl, — CH₂— and

—

NH—

;

Y is —

NH—

or oxygen;

R₁ is selected from the group consisting of halogen, substituted or unsubstituted C_1-6 alkyl, substituted aryl, aryloxy, substituted amide, sulfone, sulfonamide and C_3-7 cycloalkyl, wherein R₁ is attached ortho to the R₆O group;

R₂ and R₃ are each independently selected from the group consisting of iodo, bromo, chloro and fluoro;

R₄ is selected from the group consisting of hydrogen, fluoro, chloro, amino, —

OCH₃ and hydroxyl;

R₅ is carboxylic acid; and

R₆ is hydrogen.

3. The compound as defined in claim 1 wherein

X is selected from the group consisting of carbonyl, CHR_A and NR_A;

Y is oxygen or —

NH—

;

R₁ is selected from the group consisting of halogen, substituted or unsubstituted C_1-6 alkyl, substituted aryl, substituted amide, sulfone, sulfonamide and C_3-7 cycloalkyl;

R₂ and R₃ each independently are selected from the group consisting of bromo, chloro and methyl;

R₄ is selected from the group consisting of hydrogen, fluoro, chloro, hydroxyl, amino and methoxy;

R₅ is carboxylic acid; and

R₆ is hydrogen.

4. The compound as defined in claim 1 having the structure

5. The compound as defined in claim 4 wherein

Y is oxygen or —

NH—

;

R₂ and R₃ are halogen;

R₄ is selected from the group consisting of hydrogen, halogen, amino, —

OCH₃ and hydroxyl; and

R₁₀ is selected from the group consisting of hydrogen, halogen and substituted and unsubstituted C_1-4 alkyl.

R_1a is selected from hydrogen, methyl and ethyl.

6. The compound as defined in claim 1 having the structure

wherein R₁ is substituted or unsubstituted aryl.

7. The compound as defined in claim 1 having the structure

8. The compound as defined in claim 1 having the structure.

9. The compound as defined in claim 1 having the structure.

10. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor.

11. The pharmaceutical composition of claim 10 further comprising at least one additional therapeutic agent selected from the group consisting of other compounds of formula I, anti-diabetic agents, anti-osteoporosis agents, anti-obesity agents, growth promoting agents, anti-inflammatory agents, anti-anxiety agents, anti-depressants, anti-hypertensive agents, cardiac glycosides, cholesterol/lipid lowering agents, appetite supressants, bone resorption inhibitors, thyroid mimetics, anabolic agents, anti-tumor agents and retinoids.

12. The pharmaceutical composition of claim 11 wherein said additional therapeutic agent is an antidiabetic agent selected from the group consisting of a biguanide, a glucosidase inhibitor, a meglitinide, a sulfonylurea, a thiazolidinedione, a PPAR-alpha agonist, a PPAR-gamma agonist, a PPAR alpha/gamma dual agonist, an SGLT2 inhibitor, a glycogen phosphorylase inhibitor, an aP2 inhibitor, a glucagon-like peptide-1 (GLP-1), a dipeptidyl peptidase IV inhibitor and insulin.

13. The pharmaceutical composition of claim 11 wherein said additional therapeutic agent is an antidiabetic agent selected from the group consisting of metformin, glyburide, glimepiride, glipyride, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, troglitazone, pioglitazone, englitazone, darglitazone, rosiglitazone and insulin.

14. The pharmaceutical composition of claim 11 wherein said additional therapeutic agent is an anti-obesity agent is selected from the group consisting of an aP2 inhibitor, a PPAR gamma antagonist, a PPAR delta agonist, a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin reuptake inhibitor and an anorectic agent.

15. The pharmaceutical composition of claim 11 wherein said additional therapeutic agent is a hypolipidemic agent selected from the group consisting of a thiazolidinedione, an MTP inhibitor, a squalene synthetase inhibitor, an HMG CoA reductase inhibitor, a fibric acid derivative, an ACAT inhibitor, a cholesterol absorption inhibitor, an ileal Na⁺/bile cotransporter inhibitor, a bile acid sequestrant and a nicotinic acid or a derivative thereof.

16. A method for preventing, inhibiting or treating a disease associated with metabolism dysfunction, or which is dependent on the expression of a T₃ regulated gene, which comprises administering to a mammalian patient in need of treatment a therapeutically effective amount of a compound as defined in claim 1.

17. A method for treating or delaying the progression or onset of obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, hypothyroidism, subclinical hyperthyroidism, non-toxic goiter, reduced bone mass, density or growth, eating disorders, reduced cognitive function, thyroid cancer, glaucoma, cardiac arrhythmia, congestive heart failure or a skin disorder or disease, which comprises administering to mammalian patient in need of treatment a therapeutically effective amount of a compound as defined in claim 1.

18. The method according to claim 17 wherein the skin disorder or disease is dermal atrophy, keloids, stria, cellulite, roughened skin, actinic skin damage, lichen planus, ichtyosis, acne, psoriasis, Dernier'"'"'s disease, eczema, atopic dermatitis, chloracne, pityriasis or skin scarring.

19. The method according to claim 17 further comprising administering, concurrently or sequentially, a therapeutically effective amount of at least one additional therapeutic agent selected from the group consisting of other compounds of formula I, anti-diabetic agents, anti-osteoporosis agents, anti-obesity agents, growth promoting agents, anti-inflammatory agents, anti-anxiety agents, anti-depressants, anti-hypertensive agents, cardiac glycosides, cholesterol/lipid lowering agents, appetite supressants, bone resorption inhibitors, thyroid mimetics, anabolic agents, anti-tumor agents and retinoids.

20. A method of treating or delaying the progression or onset of a skin disorder or disease which comprises administering to a mammalian patient a therapeutically effective amount of a compound as defined in claim 1 in combination with a retinoid or a vitamin D analog.

21. A method for treating or delaying the progression or onset of obesity which comprises administering to mammalian patient in need of treatment a therapeutically effective amount of a compound as defined in claim 1.

22. A method according to claim 21 further comprising administering, concurrently or sequentially, a therapeutically effective amount of at least one additional therapeutic agent selected from the group consisting of an anti-obesity agent and an appetite suppressant.

23. A method according to claim 22 wherein said anti-obesity agent is selected from the group consisting of aP2 inhibitors, PPAR gamma antagonists, PPAR delta agonists, beta 3 adrenergic agonists, lipase inhibitors, serotonin (and dopamine) reuptake inhibitors, other thyroid receptor beta agents and anorectic agents.

25. A pharmaceutical composition which functions as a selective agonist of the thyroid hormone receptor-beta comprising a compound as defined in claim 1.

24. A compound of the formula

wherein

X is selected from the group consisting of oxygen, sulfur, sulfoxide, sulfonyl, —

CR₈R₈′ and

—

NR₈;

Y is selected from the group consisting of —

NR₈, oxygen, —

CH₂— and

sulfur;

Z is a bond or substituted or unsubstituted C_1-4 alkyl;

R₁ is selected from the group consisting of halogen, trifluoromethyl, substituted or unsubstituted C_1-6alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryloxy, substituted amide, sulfone, sulfonamide and C_3-7 cycloalkyl;

R_1a is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

R₂ and R₃ are each independently selected from the group consisting of hydrogen, halogen, unsubstituted or substituted C_1-4 alkyl and unsubstituted or substituted Cog cycloalkyl, wherein at least one of R₂ and R₃ being other than hydrogen;

R₄ is selected from the group consisting of hydrogen, halogen, amino, O—

R₇, S—

R₇ and unsubstituted or substituted C_1-4 alkyl;

R₅ is selected from the group consisting of hydroxyl, carboxylic acid, sulfonic acid and phosphonic acid;

R₆ is selected from the group consisting of hydrogen, alkyl, alkanoyl and aroyl;

R₇ is hydrogen or C_1-4 alkyl;

R₈ for each occurrence is independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, arylalkyl or substituted arylalkyl, alkoxy and hydroxyl; and

R₈′

is selected from the group consisting of hydrogen, a bond, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, arylalkyl or substituted arylalkyl, alkoxy and hydroxyl, or R₈ and R₈′

together form a carbonyl,

including all prodrug, stereoisomers and pharmaceutically acceptable salts thereof.